107 related articles for article (PubMed ID: 33200225)
1. Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells.
Lee DW; Lee W; Kwon M; Lee HN
Oncol Rep; 2021 Jan; 45(1):390-400. PubMed ID: 33200225
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer Cells.
Choi JI; Park SH; Lee HJ; Lee DW; Lee HN
PLoS One; 2016; 11(5):e0155052. PubMed ID: 27148873
[TBL] [Abstract][Full Text] [Related]
3. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
Parashar D; Nair B; Geethadevi A; George J; Nair A; Tsaih SW; Kadamberi IP; Gopinadhan Nair GK; Lu Y; Ramchandran R; Uyar DS; Rader JS; Ram PT; Mills GB; Pradeep S; Chaluvally-Raghavan P
Cancer Res; 2020 Dec; 80(24):5554-5568. PubMed ID: 33087324
[TBL] [Abstract][Full Text] [Related]
5. Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Jun; 27(5):887-894. PubMed ID: 28498253
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis induced by 7-difluoromethoxyl-5,4'-di-n-octyl genistein via the inactivation of FoxM1 in ovarian cancer cells.
Ning Y; Li Q; Xiang H; Liu F; Cao J
Oncol Rep; 2012 Jun; 27(6):1857-64. PubMed ID: 22447287
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Jane EP; Premkumar DR; Pollack IF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
[TBL] [Abstract][Full Text] [Related]
8. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Li M; Yang J; Zhou W; Ren Y; Wang X; Chen H; Zhang J; Chen J; Sun Y; Cui L; Liu X; Wang L; Wu C
Br J Cancer; 2017 Sep; 117(7):974-983. PubMed ID: 28850563
[TBL] [Abstract][Full Text] [Related]
9. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.
Ikeda Y; Park JH; Miyamoto T; Takamatsu N; Kato T; Iwasa A; Okabe S; Imai Y; Fujiwara K; Nakamura Y; Hasegawa K
Clin Cancer Res; 2016 Dec; 22(24):6110-6117. PubMed ID: 27334838
[TBL] [Abstract][Full Text] [Related]
10. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin.
Prudnikova TY; Chernoff J
Small GTPases; 2017 Oct; 8(4):193-198. PubMed ID: 27427770
[TBL] [Abstract][Full Text] [Related]
11. [Forkhead domain inhibitor-6 (FDI-6) increases apoptosis and inhibits invasion and migration of laryngeal carcinoma cells by down-regulating nuclear FoxM1].
Liu Y; Zhu L; Wen T; Wan J; Lei Y; Chen H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 May; 33(5):611-616. PubMed ID: 28502298
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}.
Mertens-Walker I; Bolitho C; Baxter RC; Marsh DJ
Endocr Relat Cancer; 2010 Jun; 17(2):335-49. PubMed ID: 20215102
[TBL] [Abstract][Full Text] [Related]
13. Forkhead Box M1 promotes the growth and tube formation of human malignant meningioma cells via the aryl hydrocarbon receptor signaling pathway.
Wu Q; Zheng J; Dou C; Qi S
Folia Neuropathol; 2020; 58(3):223-236. PubMed ID: 33099292
[TBL] [Abstract][Full Text] [Related]
14. Rottlerin inhibits stimulated enzymatic secretion and several intracellular signaling transduction pathways in pancreatic acinar cells by a non-PKC-delta-dependent mechanism.
Tapia JA; Jensen RT; García-Marín LJ
Biochim Biophys Acta; 2006 Jan; 1763(1):25-38. PubMed ID: 16364465
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
16. The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer.
Ulhaka K; Kanokwiroon K; Khongkow M; Bissanum R; Khunpitak T; Khongkow P
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206484
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 Inhibitors as Potential Diagnostic Agents: First Generation of a PET Probe Targeting FOXM1 To Detect Triple-Negative Breast Cancer in vitro and in vivo.
Pérez DJ; Amirhossein Tabatabaei Dakhili S; Bergman C; Dufour J; Wuest M; Juengling FD; Wuest F; Velázquez-Martínez CA
ChemMedChem; 2021 Dec; 16(24):3720-3729. PubMed ID: 34402202
[TBL] [Abstract][Full Text] [Related]
18. PCNA-associated factor P15
Jin C; Liu Z; Li Y; Bu H; Wang Y; Xu Y; Qiu C; Yan S; Yuan C; Li R; Diao N; Zhang Z; Wang X; Liu L; Kong B
Int J Cancer; 2018 Dec; 143(11):2973-2984. PubMed ID: 30129654
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells.
Wakino S; Kintscher U; Liu Z; Kim S; Yin F; Ohba M; Kuroki T; Schönthal AH; Hsueh WA; Law RE
J Biol Chem; 2001 Dec; 276(50):47650-7. PubMed ID: 11598137
[TBL] [Abstract][Full Text] [Related]
20. DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling.
Chan DW; Hui WW; Wang JJ; Yung MM; Hui LM; Qin Y; Liang RR; Leung TH; Xu D; Chan KK; Yao KM; Tsang BK; Ngan HY
Oncogene; 2017 Mar; 36(10):1404-1416. PubMed ID: 27593933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
